This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to
see how well they work with or without high or low-dose radiation therapy in treating
patients with colorectal or non-small cell lung cancer that has spread to other parts of the
body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in
body's immune system and may interfere with the ability of tumor cells to grow and spread.
Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving
durvalumab and tremelimumab with radiation therapy may work better in treating patients with
colorectal or non-small cell lung cancer.